Karin Tyburski

671 total citations
9 papers, 510 citations indexed

About

Karin Tyburski is a scholar working on Reproductive Medicine, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Karin Tyburski has authored 9 papers receiving a total of 510 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Reproductive Medicine, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Karin Tyburski's work include Ovarian cancer diagnosis and treatment (9 papers), Renal cell carcinoma treatment (4 papers) and Cancer Mechanisms and Therapy (3 papers). Karin Tyburski is often cited by papers focused on Ovarian cancer diagnosis and treatment (9 papers), Renal cell carcinoma treatment (4 papers) and Cancer Mechanisms and Therapy (3 papers). Karin Tyburski collaborates with scholars based in United States. Karin Tyburski's co-authors include Ursula A. Matulonis, Percy Ivy, Suzanne Berlin, Christin Whalen, Richard T. Penson, Hang Lee, Benjamin D. Humphreys, Maria Roche, Neil S. Horowitz and Susana M. Campos and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Clinical Journal of the American Society of Nephrology.

In The Last Decade

Karin Tyburski

9 papers receiving 500 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karin Tyburski United States 6 291 282 230 99 97 9 510
Josep M. del Campo Spain 10 187 0.6× 261 0.9× 131 0.6× 89 0.9× 78 0.8× 20 439
Jeffrey C. Goh Australia 11 167 0.6× 167 0.6× 109 0.5× 51 0.5× 91 0.9× 35 376
Nathalie L.G. Sieben Netherlands 8 108 0.4× 193 0.7× 195 0.8× 108 1.1× 50 0.5× 8 433
Ingirídur Skírnisdóttir Sweden 16 234 0.8× 499 1.8× 176 0.8× 87 0.9× 77 0.8× 26 682
Betül T. Yesilyurt Belgium 8 194 0.7× 79 0.3× 184 0.8× 71 0.7× 89 0.9× 9 452
S. Loibl Germany 10 254 0.9× 227 0.8× 93 0.4× 49 0.5× 123 1.3× 30 516
Hal Hirte Canada 8 149 0.5× 89 0.3× 155 0.7× 49 0.5× 45 0.5× 11 333
Antje Belau Germany 14 312 1.1× 255 0.9× 161 0.7× 134 1.4× 61 0.6× 42 678
Catherine J. Kennedy Australia 13 194 0.7× 85 0.3× 234 1.0× 39 0.4× 176 1.8× 25 560
Christopher DiSimone United States 6 271 0.9× 133 0.5× 114 0.5× 60 0.6× 148 1.5× 10 490

Countries citing papers authored by Karin Tyburski

Since Specialization
Citations

This map shows the geographic impact of Karin Tyburski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Tyburski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Tyburski more than expected).

Fields of papers citing papers by Karin Tyburski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Tyburski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Tyburski. The network helps show where Karin Tyburski may publish in the future.

Co-authorship network of co-authors of Karin Tyburski

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Tyburski. A scholar is included among the top collaborators of Karin Tyburski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Tyburski. Karin Tyburski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Campos, Susana M., Suzanne Berlin, Carolyn Krasner, et al.. (2022). A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies. Cancer Chemotherapy and Pharmacology. 89(3). 423–430. 4 indexed citations
2.
Liu, Joyce F., Sara M. Tolaney, Michael J. Birrer, et al.. (2013). A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. European Journal of Cancer. 49(14). 2972–2978. 130 indexed citations
3.
Campos, Susana M., Richard T. Penson, Ursula A. Matulonis, et al.. (2012). A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecologic Oncology. 128(2). 215–220. 41 indexed citations
4.
Fleming, Gini F., Sara M. Tolaney, M. J. Birrer, et al.. (2011). A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 5028–5028. 13 indexed citations
5.
Robinson, Emily, Ursula A. Matulonis, Percy Ivy, et al.. (2010). Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor. Clinical Journal of the American Society of Nephrology. 5(3). 477–483. 61 indexed citations
6.
Matulonis, Ursula A., Suzanne Berlin, Percy Ivy, et al.. (2009). Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. Journal of Clinical Oncology. 27(33). 5601–5606. 233 indexed citations
7.
Matulonis, Ursula A., Suzanne Berlin, Carolyn Krasner, et al.. (2008). Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. Journal of Clinical Oncology. 26(15_suppl). 5501–5501. 23 indexed citations
8.
Matulonis, Ursula A., Suzanne Berlin, Carolyn Krasner, et al.. (2007). Phase II study of Cediranib (RECENTIN™, AZD2171) in recurrent epithelial ovarian cancer. Molecular Cancer Therapeutics. 6. 1 indexed citations
9.
Krasner, Carolyn, Michael V. Seiden, Arlan F. Fuller, et al.. (2006). Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. Journal of Clinical Oncology. 24(18_suppl). 5008–5008. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Josep M. del Campo Breakdown of academic impact, for papers by Jeffrey C. Goh Breakdown of academic impact, for papers by Nathalie L.G. Sieben Breakdown of academic impact, for papers by Ingirídur Skírnisdóttir Breakdown of academic impact, for papers by Betül T. Yesilyurt Breakdown of academic impact, for papers by S. Loibl Breakdown of academic impact, for papers by Hal Hirte Breakdown of academic impact, for papers by Antje Belau Breakdown of academic impact, for papers by Catherine J. Kennedy Breakdown of academic impact, for papers by Christopher DiSimone
Rankless by CCL
2026